Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875710 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL585441 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL4579011 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL7515272 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL876407 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL4580702 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL4579395 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL3986297 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL6561802 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL7523852 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773222-B | Synthesis method of azo micromolecules for zinc oxide nanoparticle stable ligand | 宁波大学 | 2024-04-09 | — | — | CN | claimed |
| CN-114773222-A | Synthetic method of azo micromolecules for zinc oxide nanoparticle stable ligand | 宁波大学 | 2022-07-22 | — | — | CN | claimed |
| CN-104725383-B | Pyrrolo-pyrrole-dione (DPP) quaternary ammonium compound and its preparation and use | 华东理工大学 | 2017-04-05 | — | — | CN | claimed |
| US-4167638-A | Process for production of 8-NHR quinolines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1979-09-11 | — | — | US | claimed |
| JP-9299086-A | — | — | None | — | — | JP | disclosed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743555-A1 | PHTHALIMIDE COMPOUNDS AS BASE OIL FOR LUBRICANT COMPOSITIONS | Klueber Lubrication München GmbH & Co. KG (DE) | 2026-05-20 | — | — | EP | disclosed |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4700124-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2025-12-23 | — | — | US | disclosed |
| EP-0099785-A2 | Amino and substituted amino phosphinylalkanoyl compounds | E.R. Squibb & Sons, Inc. (US) | 1984-02-01 | — | — | EP | disclosed |
| EP-0071544-A1 | Phosphonamidate compounds | E.R. Squibb & Sons, Inc. (US) | 1983-02-09 | — | — | EP | disclosed |
| US-4334069-A | Chemiluminescent phthalhydrazide-labeled hapten conjugates | MILES LABORATORIES, INC. (US) | 1982-06-08 | — | — | US | disclosed |
| US-4297273-A | MEDICAL DIAGNOSIS; IMMUNOASSAY | MILES LABORATORIES, INC. (US) | 1981-10-27 | — | — | US | disclosed |
| EP-0029306-A1 | Aminoalkyl compounds, their production and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1981-05-27 | — | — | EP | disclosed |
| US-4226993-A | INTERMEDIATES FOR CHEMILUMINESCENT LABELED CONJUGATES | MILES LABORATORIES, INC. (US) | 1980-10-07 | — | — | US | disclosed |
| US-4212805-A | INTERMEDIATES OF PHTHALHYDRAZIDE-LABELED CONJUGATES | MILES LABORATORIES, INC. (US) | 1980-07-15 | — | — | US | disclosed |
| US-4167638-A | Process for production of 8-NHR quinolines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | EZH2, BMI1, SUZ12 | TDP1 3035/4885L3MBTL1 886/4885CHRM2 4736/4885 |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | TDP1 1354/4885L3MBTL1 2391/4885CHRM2 4879/4885 |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | TDP1 683/4885L3MBTL1 857/4885CHRM2 2593/4885 |
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | GRPR, HSPB1, HSP90AB2P | TDP1 3007/4885L3MBTL1 3363/4885CHRM2 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.